C-A1SWViscient Bio
3D tissue models, multi-omics, drug discovery
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-A1SW
C-A1SWC-A1SW3D tissue models, multi-omics, drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Viscient Bio 3D tissue models, multi-omics, drug discovery
Viscient Biosciences is a San Diego-based biotechnology company working at the intersection of human 3D tissue technology and multi-omics analysis. The company uses three-dimensional disease models made from human cells to discover disease drivers and develop drugs. Its initial discovery and development work is in non-alcoholic steatohepatitis, and the site says it has advanced one drug to the preclinical level while preparing it for Phase 1 studies.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Viscient Bio — Early mechanism · Lower middle. Derived deterministically from 5 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic